- Home
- CRBP vs CURV Comparison
CRBP vs CURV Comparison
Compare CRBP & CURV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRBP | CURV |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 169.8M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRBP | CURV |
|---|---|---|
| Price | $10.59 | $2.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $45.60 | $1.59 |
| AVG Volume (30 Days) | 237.0K | ★ 411.0K |
| Earning Date | 05-08-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,822,272.00 | ★ $1,000,092,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $116.00 | $1.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $6.10 | $0.94 |
| 52 Week High | $20.56 | $6.69 |
Technical Indicators
Market Signals| Indicator | CRBP | CURV |
|---|---|---|
| Relative Strength Index (RSI) | 59.58 | 83.08 |
| Support Level | $7.91 | $2.08 |
| Resistance Level | $10.62 | $2.40 |
| Average True Range (ATR) | 0.66 | 0.14 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 63.67 | 89.08 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.